Dr. Elżbieta Złowocka-Perłowska | kidney cancer | Best Researcher Award
Department of Genetics and Pathology, International Hereditary Cancer Center, Pomeranian Medical University | Poland
PUBLICATION PROFILE
Orcid
Dr. Elżbieta Złowocka-Perłowska⚡🌍
INTRODUCTION 🌟
Dr. Elżbieta Złowocka-Perłowska is a distinguished academic and researcher at the Pomeranian Medical University, specializing in clinical genetics, molecular biology, and hereditary cancers. With over two decades of dedication to the Hereditary Cancer Center at the Department of Genetics and Pathomorphology, she has become an influential figure in medical sciences, particularly focusing on bladder and kidney cancer research. Her work aims to integrate trace element analysis into personalized cancer treatment models, contributing significantly to the field of molecular genetics.
EARLY ACADEMIC PURSUITS 🎓
Dr. Złowocka-Perłowska’s academic journey began with a diploma in Biology from the University of Szczecin in 2002. She then pursued a PhD in Medical Sciences at Pomeranian Medical Academy in Szczecin, where she earned her degree with distinction in 2008. Throughout her early academic years, she demonstrated a deep commitment to the study of genetics and its implications for cancer research.
PROFESSIONAL ENDEAVORS 💼
Since 2002, Dr. Złowocka-Perłowska has been associated with the Hereditary Cancer Center at the Pomeranian Medical University. Her career has evolved from a PhD student to a University Lecturer, Assistant Professor, and National Consultant in Clinical Genetics. She has taught both Polish and English-language courses across various medical and biotechnology programs. Dr. Złowocka-Perłowska’s professional endeavors have led her to direct research projects on cancer diagnostics, utilizing molecular techniques like MLPA, TaqMan, and NGS.
CONTRIBUTIONS AND RESEARCH FOCUS ON kidney cancer🔬
Dr. Złowocka-Perłowska’s research is centered on the study of hereditary cancers, particularly bladder and kidney cancers. Her current research project aims to explore the role of trace elements in cancer prognosis, with a specific focus on blood and serum selenium levels as potential markers for survival. She has conducted extensive studies using molecular genetics techniques and has made significant contributions to the understanding of hereditary cancer genetics. Her scientific work has culminated in 51 publications, four patents (including an international patent), and numerous conference presentations.
IMPACT AND INFLUENCE 🌍
As a recognized leader in the field of hereditary cancer research, Dr. Złowocka-Perłowska has had a profound impact on both medical education and healthcare. Her contributions to clinical studies, research, and the advancement of cancer treatments have been recognized internationally. Through her scientific publications and involvement in research projects, she continues to influence the development of personalized medicine and clinical genetics.
ACADEMIC CITATIONS AND PUBLICATIONS 📚
Dr. Złowocka-Perłowska is the author and co-author of numerous scientific papers published in national and international journals. Her work focuses on hereditary cancers and molecular biology, contributing to the advancement of clinical genetics. With 51 publications to her name, her research is frequently cited by peers in the scientific community. Her papers have been presented at several renowned scientific conferences, establishing her as a thought leader in her field.
HONORS & AWARDS 🏆
Dr. Złowocka-Perłowska has received numerous accolades throughout her career, including the Minister of Health’s Team Award in 2005 and the prestigious “Eminent Scientist of the Year 2009” award from the World Scientist Forum International Awards. She has also been honored with multiple Rector’s Awards for her scientific achievements at Pomeranian Medical University. Other recognitions include certifications for NGS sequencing training and contributions to laboratory medical genetics.
FINAL NOTE ✨
Dr. Złowocka-Perłowska’s work is a testament to the power of academic dedication and scientific inquiry. Her commitment to advancing medical genetics, particularly in the study of hereditary cancers, has significantly shaped the field. Through her research, teaching, and clinical contributions, she continues to inspire future generations of scientists and clinicians.
LEGACY AND FUTURE CONTRIBUTIONS 🔮
Dr. Złowocka-Perłowska’s ongoing research on cancer treatment and prognostic markers positions her as a key figure in the evolution of personalized medicine. With her focus on integrating molecular techniques and trace element analysis, her future contributions will likely continue to revolutionize cancer diagnostics and treatment. She leaves a lasting legacy in the field of medical genetics, with a promising trajectory for further scientific discovery.
TOP NOTES PUBLICATIONS 📚
1. Blood and Serum Copper and Zinc Levels and 10-Year Survival of Patients After Kidney Cancer Diagnosis
- Authors: Elżbieta Złowocka-Perłowska, Piotr Baszuk, Wojciech Marciniak, Róża Derkacz, Aleksandra Tołoczko-Grabarek, Katarzyna Gołębiewska, Marcin Słojewski, Adam Gołąb, Artur Lemiński, Michał Soczawa, et al.
- Journal: Nutrients
- Year: 2025
- DOI: 10.3390/nu17060944
2. Germline BRCA1 and BRCA2 mutations and the risk of bladder or kidney cancer in Poland
- Authors: Elżbieta Złowocka-Perłowska, Aleksandra Tołoczko-Grabarek, Steven A. Narod, Jan Lubiński
- Journal: Hereditary Cancer in Clinical Practice
- Year: 2022
- DOI: 10.1186/s13053-022-00220-6
3. Germline HOXB13 mutation p.G84E do not confer an increased bladder or kidney cancer risk in Polish population
- Authors: Elżbieta Złowocka-Perłowska, Aleksandra Tołoczko-Grabarek, Jan Lubiński
- Journal: Hereditary Cancer in Clinical Practice
- Year: 2022
- DOI: 10.1186/s13053-021-00208-8
4. Recurrent PALB2 mutations and the risk of cancers of bladder or kidney in Polish population
- Authors: Elżbieta Złowocka-Perłowska, Aleksandra Tołoczko-Grabarek, Jan Lubiński
- Journal: Hereditary Cancer in Clinical Practice
- Year: 2021
- DOI: 10.1186/s13053-020-00161-y
5. Survival of bladder or renal cancer in patients with CHEK2 mutations
- Authors: Elżbieta Złowocka-Perłowska, Alvaro Galli, Tadeusz Dębniak, Marcin Słojewski, Thierry van de Wetering, Aleksandra Tołoczko-Grabarek, Cezary Cybulski, Rodney J. Scott, Jan Lubiński
- Journal: PLOS ONE
- Year: 2021
- DOI: 10.1371/journal.pone.0257132